Avulux Lens for Migraine Light Sensitivity Wins FDA De Novo Nod

Avulux, maker of light-filtering lenses for people with migraine and light sensitivity, has received U.S. Food and Drug Administration (FDA) de novo authorization.

For millions with migraine, light can trigger or worsen pain, disrupting work and daily life. Despite being one of the condition’s most common symptoms, light sensitivity has lacked an FDA-authorized treatment option until now.

Avulux is a precision optical filter designed to block light at 480 nm and 590 nm while allowing other visible wavelengths to pass through, reducing light sensitivity in patients 12 and older with episodic migraine. Worn like standard eyeglasses, it is available with or without a prescription and is intended to complement, not replace, usual migraine therapy.

The authorization establishes a defined, FDA-recognized classification for Avulux.

Comments from Avulux and others

Dr. Charles Posternack, co-founder and CEO: “For a long time, light sensitivity was seen as just a symptom of migraine. That thinking has changed. There is growing recognition that light sensitivity is a serious medical concern in its own right. This authorization gives patients and providers a clear, FDA-recognized option designed specifically to manage the impact of light in those with migraine, one we hope will soon become the standard of medical care in this population.”

Juan Espinoza, MD, director and principal investigator of the Consortium for Technology & Innovation in Pediatrics: “Migraines in children are often underdiagnosed and undertreated, despite their profound impact on development, education, and overall well-being. At CTIP, we are committed to supporting innovations like Avulux that offer non-invasive and effective solutions to improve the lives of pediatric patients.”